New analysis prompts hope for hydromethylthionine in Alzheimer's

27 November 2019
claude_wischik_taurx_big

Singapore-based TauRx has announced the publication of unexpected results of its drug hydromethylthionine, or LMTM, in patients with mild-to-moderate Alzheimer's disease.

In the online issue of the Journal of Alzheimer's Disease, the results have been published of a pharmacokinetic analysis of the relationship between treatment dose, blood levels and pharmacological activity of the drug on the brain in patients with the disease.

Top tau prospect

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biotechnology